Note 7 - Accrued Expenses - Restructuring Activity 1 (Details) - Severance and Benefits Costs [Member] - Pieris Pharmaceuticals, Inc. [Member] - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | 12 Months Ended | |
|---|---|---|---|---|
Sep. 30, 2024 |
Sep. 30, 2024 |
Dec. 31, 2023 |
Jun. 30, 2024 |
|
| Restructuring expenses | $ 805 | $ 2,791 | $ 7,523 | |
| Cash payments | (2,418) | |||
| Ending balance | $ 2,228 | $ 2,228 | $ 5,105 | $ 2,850 |
| X | ||||||||||
- Definition Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|